Applied Therapeutics (APLT) Price & Analysis

Compare

834 Followers

APLT Stock Chart & Stats

$1.15

-$0.07(-8.39%)

At close: Jan 08 4:00 PM EST

$1.15

-$0.07(-8.39%)

Day’s Range― - ―

52-Week Range$0.30 - $10.62

Previous CloseN/A

Volume3.84M

Average Volume (3M)8.56M

Market Cap

$164.17M

Enterprise Value$17.32M

Total Cash (Recent Filing)$30.42M

Total Debt (Recent Filing)$2.60M

Price to Earnings (P/E)―

Beta1.43

Next Earnings

Nov 06, 2025

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding144,012,130

10 Day Avg. Volume8,453,371

30 Day Avg. Volume8,561,033

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.11

Enterprise Value/Revenue141.96

Enterprise Value/Gross Profit-279.34

Enterprise Value/Ebitda-0.16

Forecast

1Y Price Target

$2.25

Price Target Upside95.65% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Market SentimentThe stock is up about 80% during market hours, indicating positive market sentiment based on the clinical trial entry.

Regulatory ProgressA new clinical trial entry suggests that the company may have aligned on accelerated approval for their drug Govorestat in SORD.

Strategic PartnershipsThe company entered an outlicensing agreement with Biossil, Inc. for AT-001, its investigational aldose reductase inhibitor (ARI) for diabetic cardiomyopathy (DbCM).

Bears Say

Financial StabilityThe company bears increased financial risk due to its limited cash runway of $30.4 million as of June 30.

NDA Submission ChallengesThe company has not explicitly stated that conversations with the FDA support the submission of an NDA or the potential timing of the submission.

Regulatory UncertaintyRegulatory path for Govorestat remains uncertain pending the official meeting minutes before finalizing its regulatory submission strategy.

Applied Therapeutics News

Applied Therapeutics completes FDA meeting on potential NDA for govorestat

Applied Therapeutics (APLT) announced that the Company completed a meeting with the U.S. Food and Drug Administration to...

17d ago

APLT

Applied Therapeutics up after details posted for confirmatory govorestat study

Applied Therapeutics (APLT) shares have advanced after the clinicaltrials.gov website was updated to show details about a planned...

20d ago

APLT

Applied Therapeutics Announces New Equity Offering Agreement

The latest update is out from Applied Therapeutics ( ($APLT) ). On August 29, 2025, Applied Therapeutics, Inc....

2M ago

APLT

Strategic Positioning and Growth Potential: Joseph Schwartz’s Buy Rating on Applied Therapeutics

Analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on Applied Therapeutics, with a price target of...

2M ago

APLT

Applied Therapeutics Granted Nasdaq Compliance Extension

The latest announcement is out from Applied Therapeutics ( ($APLT) ). Applied Therapeutics, Inc. received a notification from...

2M ago

APLT

Applied Therapeutics Advances Pipeline Amid Financial Challenges

Applied Therapeutics ( ($APLT) ) has released its Q2 earnings. Here is a breakdown of the information Applied...

2M ago

APLT

Applied Therapeutics reports Q2 EPS (15c), consensus (16c)

Cash and cash equivalents totaled $30.4M as of June 30, 2025 vs. $79.4M at December 31, 2024.”The first...

2M ago

APLT

Applied Therapeutics Faces Nasdaq Listing Challenge

Applied Therapeutics ( ($APLT) ) has issued an announcement. On February 7, 2025, Applied Therapeutics received a notification...

2M ago

APLT

Applied Therapeutics Announces New Chief Medical Officer

Applied Therapeutics ( ($APLT) ) just unveiled an announcement. On June 17, 2025, Applied Therapeutics announced the departure...

4M ago

APLT

Applied Therapeutics CMO Riccardo Perfetti to depart, Evan Bailey to succeed

Applied Therapeutics (APLT) announced the promotions of Evan Bailey to chief medical officer, effective June 15 and Dottie...

4M ago

APLT

Applied Therapeutics Elects New Director at Annual Meeting

The latest update is out from Applied Therapeutics ( ($APLT) ). At the 2025 Annual Meeting of Stockholders...

4M ago

APLT

Hold Rating for Applied Therapeutics Amid Mixed Results from Govorestat Trial

William Blair analyst Sami Corwin has reiterated their neutral stance on APLT stock, giving a Hold rating on...

5M ago

APLT

Applied announces INSPIRE Phase 2/3 trial primary endpoint not significant

Applied Therapeutics (APLT) presented full 12-month clinical results and new topline data from 18 and 24 months from...

5M ago

APLT

Strategic Advancements and Regulatory Progress Drive Buy Rating for Applied Therapeutics

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Applied Therapeutics (APLT – Research Report) on May...

5M ago

APLT

APLT FAQ

What was Applied Therapeutics Inc’s price range in the past 12 months?

Applied Therapeutics Inc lowest stock price was $0.29 and its highest was $10.62 in the past 12 months.

What is Applied Therapeutics Inc’s market cap?

Applied Therapeutics Inc’s market cap is $164.17M.

When is Applied Therapeutics Inc’s upcoming earnings report date?

Applied Therapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 21 days.

How were Applied Therapeutics Inc’s earnings last quarter?

Applied Therapeutics Inc released its earnings results on Aug 13, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.165 by $0.015.

Is Applied Therapeutics Inc overvalued?

According to Wall Street analysts Applied Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Applied Therapeutics Inc pay dividends?

Applied Therapeutics Inc does not currently pay dividends.

What is Applied Therapeutics Inc’s EPS estimate?

Applied Therapeutics Inc’s EPS estimate is -0.14.

How many shares outstanding does Applied Therapeutics Inc have?

Applied Therapeutics Inc has 144,012,130 shares outstanding.

What happened to Applied Therapeutics Inc’s price movement after its last earnings report?

Applied Therapeutics Inc reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.165. Following the earnings report the stock price went up 4.444%.

Which hedge fund is a major shareholder of Applied Therapeutics Inc?

Currently, no hedge funds are holding shares in APLT

Applied Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-150.82%

Trailing 12-Months

Asset Growth

-70.78%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Applied Therapeutics Inc

Applied Therapeutics (APLT) is a clinical-stage biopharmaceutical company dedicated to developing transformative treatments for patients with high unmet medical needs. The company focuses on novel drug candidates designed to address central nervous system and metabolic disorders. Its core products are centered around small molecules targeting critical pathways involved in disease progression. Applied Therapeutics aims to leverage its scientific expertise to bring innovative therapies from research to commercialization.

Applied Therapeutics (APLT) Earnings & Revenues

Historic Earnings Reports

APLT Stock 12 Month Forecast

Average Price Target

$2.25

▲(95.65% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.52,0.7107692307692308,0.9015384615384616,1.0923076923076924,1.2830769230769232,1.473846153846154,1.6646153846153846,1.8553846153846154,2.046153846153846,2.236923076923077,2.4276923076923076,2.6184615384615384,2.809230769230769,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.52,0.6530769230769231,0.7861538461538462,0.9192307692307692,1.0523076923076924,1.1853846153846153,1.3184615384615384,1.4515384615384614,1.5846153846153845,1.7176923076923076,1.8507692307692307,1.9838461538461538,2.1169230769230767,{"y":2.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.52,0.5953846153846154,0.6707692307692308,0.7461538461538462,0.8215384615384616,0.8969230769230769,0.9723076923076923,1.0476923076923077,1.123076923076923,1.1984615384615385,1.2738461538461539,1.3492307692307692,1.4246153846153846,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.33,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.44,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.61,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.66,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.34,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.39,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.46,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.41,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >